Amneal Pharmaceuticals (NYSE:AMRX) Upgraded to “Hold” by Zacks Investment Research
According to Zacks, “Amneal Pharmaceuticals LLC is an integrated specialty pharmaceutical company. It focused on developing, manufacturing and distributing generic, brand and biosimilar products. The company operates primarily in North America, Asia and Europe. Amneal Pharmaceuticals LLC, formerly known as Impax Laboratories Inc., is based in New Jersey, United States. “
Other analysts have also recently issued research reports about the stock. SunTrust Banks reaffirmed a “buy” rating and set a $5.00 price target on shares of Amneal Pharmaceuticals in a research report on Tuesday, August 6th. Raymond James cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and cut their price target for the company from $13.00 to $8.50 in a report on Wednesday, July 10th. Cantor Fitzgerald reduced their price objective on shares of Amneal Pharmaceuticals from $35.00 to $14.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 12th. Leerink Swann upgraded shares of Amneal Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, July 22nd. Finally, Royal Bank of Canada cut shares of Amneal Pharmaceuticals from an “outperform” rating to a “sector perform” rating and dropped their target price for the stock from $11.00 to $6.00 in a research report on Thursday, July 11th. One analyst has rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the company. Amneal Pharmaceuticals has a consensus rating of “Hold” and an average target price of $9.65.
Amneal Pharmaceuticals (NYSE:AMRX) last posted its quarterly earnings data on Monday, August 5th. The company reported $0.09 EPS for the quarter, missing the Zacks’ consensus estimate of $0.14 by ($0.05). Amneal Pharmaceuticals had a negative net margin of 3.65% and a positive return on equity of 28.20%. The firm had revenue of $404.60 million during the quarter, compared to the consensus estimate of $420.12 million. During the same period in the prior year, the company posted $0.24 earnings per share. The company’s revenue for the quarter was down 12.5% compared to the same quarter last year. Equities analysts forecast that Amneal Pharmaceuticals will post 0.51 earnings per share for the current fiscal year.
In other Amneal Pharmaceuticals news, Director Ted C. Nark acquired 50,000 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were acquired at an average price of $2.39 per share, for a total transaction of $119,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Andrew S. Boyer acquired 66,666 shares of the business’s stock in a transaction on Wednesday, August 7th. The stock was acquired at an average price of $2.89 per share, for a total transaction of $192,664.74. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 1,788,966 shares of company stock worth $5,377,057. 26.34% of the stock is owned by insiders.
Hedge funds have recently added to or reduced their stakes in the company. First Mercantile Trust Co. increased its stake in Amneal Pharmaceuticals by 40.9% in the 1st quarter. First Mercantile Trust Co. now owns 11,932 shares of the company’s stock worth $169,000 after acquiring an additional 3,461 shares during the last quarter. Swiss National Bank boosted its stake in Amneal Pharmaceuticals by 2.1% during the 2nd quarter. Swiss National Bank now owns 171,200 shares of the company’s stock worth $1,228,000 after purchasing an additional 3,600 shares during the last quarter. Commerce Bank grew its holdings in shares of Amneal Pharmaceuticals by 17.8% during the first quarter. Commerce Bank now owns 23,935 shares of the company’s stock worth $339,000 after buying an additional 3,625 shares in the last quarter. Bank of Montreal Can raised its position in shares of Amneal Pharmaceuticals by 87.5% in the second quarter. Bank of Montreal Can now owns 8,475 shares of the company’s stock valued at $60,000 after buying an additional 3,954 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of Amneal Pharmaceuticals by 790.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,766 shares of the company’s stock valued at $56,000 after buying an additional 6,894 shares during the last quarter. Hedge funds and other institutional investors own 34.79% of the company’s stock.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Featured Story: What is Put Option Volume?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.